Valuation: Resverlogix Corp.

Market Cap 23.04M 16.23M 14.32M 13.55M 12.29M 1.56B 23.27M 163M 62.65M 795M 60.93M 59.61M 2.56B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 109M 76.66M 67.65M 64.01M 58.05M 7.36B 110M 768M 296M 3.76B 288M 282M 12.09B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.44%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
1 week+11.76%
6 months-13.64%
Current year-5.00%
1 week 0.09
Extreme 0.09
0.12
1 month 0.08
Extreme 0.085
0.12
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap. Importance
7/6/26 Option

Chief Financial Officer

350,000 0.1018%
7/6/26 Option

Chief Financial Officer

-350,000 0.1018%
7/6/26 Option

Chief Executive Officer

500,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%+11.76%-9.52%+35.71% 24.3M
-0.70%-4.28%+52.62%+86.42% 71.81B
+0.45%-0.82%+38.81%+84.19% 60.06B
+3.64%+5.02%+35.31%+24.75% 27.93B
-1.73%-4.30%-18.37%+357.94% 25.7B
-0.51%-2.28%+0.48%-9.27% 24.89B
+0.65%+1.67%+26.47%-7.62% 20.92B
+3.46%+3.02%+158.90%+337.81% 15.04B
+0.48%+0.86%+44.56%+168.42% 14.46B
+4.19%+2.03%-4.12%+526.97% 13.87B
Average +0.49%-0.13%+32.51%+160.53% 27.47B
Weighted average by Cap. +0.55%-1.84%+37.01%+129.55%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.38M -4.75M -4.49M -4.07M -516M -7.71M -53.87M -20.76M -264M -20.19M -19.75M -848M -7.77M -5.47M -4.83M -4.57M -4.14M -525M -7.84M -54.8M -21.12M -268M -20.54M -20.1M -863M
Net Debt 81.87M 57.67M 50.89M 48.15M 43.67M 5.53B 82.68M 578M 223M 2.83B 217M 212M 9.09B 85.79M 60.43M 53.33M 50.46M 45.76M 5.8B 86.64M 605M 233M 2.96B 227M 222M 9.53B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-09-29 $0.0950 -5.00% 61,178
26-09-28 $0.1000 -4.76% 8,000
26-09-25 $0.1050 +16.67% 113,926
26-09-24 $0.0900 0.00% 3,000
26-09-23 $0.0900 +5.88% 35,685